45 completed. 45 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 45 | Completed 45 |
| Phase 2 | 1 | Completed 1 |
Follow Mania: new trials by email Literature Review of Mania trials Research Report on Mania
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BHV-7000 Acute Treatment of Bipolar Mania BHV-7000, Placebo - Bipolar Disorder | Phase 2 / Phase 3 | Completed | Biohaven Therapeutics Ltd. | 274 | 2024-05-28 | 2025-12-16 |
| A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania Probio-Tec BG-VCap-6.5, Placebo - Mania (Neurotic) | Phase 3 | Completed | University of Texas Southwestern Medical Center | 67 | 2018-09-06 | 2025-12-19 |
| A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features Cariprazine, Placebo - Bipolar I Disorder, Mania | Phase 3 | Completed | AbbVie | 901 | 2018-06-15 | 2023-09-28 |
| A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Brexpiprazole - Bipolar I Disorder, Acute Mania | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 381 | 2017-10-24 | 2020-08-17 |
| A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Brexpiprazole, Placebo - Bipolar I Disorder, Manic Episode | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 333 | 2017-09-19 | 2020-02-11 |
| A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Brexpiprazole, Placebo - Bipolar I Disorder, Manic Episode | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 322 | 2017-09-14 | 2020-02-10 |
| Methylphenidate for the Treatment of Acute Mania methylphenidate, Placebo - Mania | Phase 3 | Completed | Michael Kluge | 42 | 2012-03-01 | 2016-06-10 |
| Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Citicoline, Placebo - Mania, Hypomania | Phase 3 | Completed | University of Texas Southwestern Medical Center | 44 | 2010-07-01 | 2014-08-11 |
| Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode Allopurinol, Placebo - Mania | Phase 3 | Completed | Sheba Medical Center | 180 | 2010-05-01 | 2012-05-08 |
| Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder Cariprazine - Bipolar I Disorder | Phase 3 | Completed | Forest Laboratories | 403 | 2010-02-28 | 2019-06-13 |
| Safety and Efficacy of Cariprazine for Bipolar I Disorder Cariprazine, Placebo - Mania, Bipolar I Disorder | Phase 3 | Completed | Forest Laboratories | 497 | 2010-02-01 | 2017-04-12 |
| Safety and Efficacy of Cariprazine for Mania Cariprazine, Placebo - Bipolar Disorder, Mania | Phase 3 | Completed | Forest Laboratories | 323 | 2010-02-01 | 2017-04-17 |
| Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes Phenytoin (brand name Dilantin), Hydrocortisone, Placebo - Healthy | Phase 3 | Completed | University of Texas Southwestern Medical Center | 17 | 2008-01-01 | 2015-08-19 |
| Phase 3 /Seroquel SR Acute Mania Monotherapy - US Quetiapine fumarate (Seroquel) SR - Affective Psychosis, Bipolar, Manic Disorder | Phase 3 | Completed | AstraZeneca | 447 | 2007-01-01 | 2009-03-25 |
| A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder Olanzapine, Paliperidone ER, Placebo - Bipolar Disorder | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 768 | 2006-05-01 | 2015-04-15 |
| A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder Placebo, Quetiapine, Paliperidone ER - Bipolar Disorder, Mood Disorders | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 493 | 2006-04-01 | 2014-06-20 |
| A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder Paliperidone ER - Affective Psychosis, Bipolar, Bipolar Disorder | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 300 | 2006-04-01 | 2011-05-18 |
| A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder Paliperidone extended-release - Bipolar Disorder, Mood Disorders | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 473 | 2006-02-01 | 2011-06-09 |
| Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder olanzapine, lithium, valproate - Manic or Mixed Episode Associated With Bipolar I Disorder | Phase 3 | Completed | Eli Lilly and Company | 139 | 2005-11-01 | 2010-12-28 |
| Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients Quetiapine Fumarate, Lithium - Mania, Bipolar Disorder | Phase 3 | Completed | AstraZeneca | 150 | 2005-08-01 | 2010-12-09 |
Showing 20 of 45. Sign in to see all of them.
Bipolar Disorder (32) · Affective Disorders, Psychotic (5) · Psychotic Disorders (5) · Depression (4) · Mood Disorders (4) · Schizophrenia (2) · Cocaine-Related Disorders (1) · Mental Disorders (1) · Teratogenesis (1)
Nervous System Diseases (45) · Neurobehavioral Manifestations (45) · Neurologic Manifestations (45) · Pathological Conditions, Signs and Symptoms (45) · Signs and Symptoms (45) · Mental Disorders (33) · Bipolar and Related Disorders (32) · Mood Disorders (28) · Schizophrenia Spectrum and Other Psychotic Disorders (10) · Behavior (4) · Behavioral Symptoms (4) · Chemically-Induced Disorders (1) · Pathologic Processes (1) · Substance-Related Disorders (1)
Risperidone (7) · Topiramate (5) · Valproic Acid (5) · 10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide (4) · Lithium (4) · Quetiapine Fumarate (4) · cariprazine (4) · Olanzapine (3) · Paliperidone Palmitate (3) · brexpiprazole (3) · Aripiprazole (2) · Lithium Carbonate (2) · Adrenal Cortex Hormones (1) · Allopurinol (1) · Carbamazepine (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (13) · Otsuka Pharmaceutical Development & Commercialization, Inc. (5) · Abbott (3) · Forest Laboratories (3) · Novartis Pharmaceuticals (3) · University of Texas Southwestern Medical Center (3) · AstraZeneca (2) · Eli Lilly and Company (2) · AbbVie (1) · Beersheva Mental Health Center (1) · Biohaven Therapeutics Ltd. (1) · Janssen Pharmaceutica N.V., Belgium (1) · Michael Kluge (1) · Novartis (1) · Ortho-McNeil Neurologics, Inc. (1)
United States (26) · Ukraine (7) · Russia (6) · Poland (5) · Serbia (5) · Bulgaria (4) · Croatia (3) · Germany (3) · Romania (3) · China (2) · France (2) · Hungary (2) · India (2) · Israel (2) · Japan (2)
Elizabeth Diaz, MD (3) · Matthew Leoni, M.D. (2) · Alan G. Mallinger, M.D. (1) · Barbara Geller, MD (1) · Catherine Datto, MD (1) · Clara Gu (1) · E. Sherwood Brown, PH.D., M.D. (1)
PMID 19325497, PMID 29017067, PMID 31344528, PMID 12091192, PMID 12562742, PMID 15169694, PMID 15572276, PMID 16086617, PMID 16135859, PMID 17107240, PMID 17335331, PMID 19594501, PMID 19906348, PMID 20361904, PMID 20565430, PMID 20624657, PMID 20947174, PMID 21823911, PMID 22054797, PMID 22134043, PMID 22213771, PMID 22377512, PMID 22917200, PMID 23437959, PMID 23480324, PMID 25562205, PMID 26598475, PMID 26598476, PMID 28843918, PMID 29174864, PMID 35235061
2017 (2), R01MH069801 (1), U01MH064846 (1), U01MH064850 (1), U01MH064868 (1), U01MH064869 (1), U01MH064887 (1), U01MH064911 (1)